Cryo-Cell International Inc. (NYSEAMERICAN:CCEL – Get Free Report) was the target of a large decrease in short interest in August. As of August 31st, there was short interest totaling 5,662 shares, a decrease of 55.5% from the August 15th total of 12,737 shares. Based on an average daily trading volume, of 19,110 shares, the short-interest ratio is presently 0.3 days. Approximately 0.1% of the shares of the stock are sold short.
Hedge Funds Weigh In On Cryo-Cell International
A hedge fund recently raised its stake in Cryo-Cell International stock. Susquehanna International Group LLP lifted its stake in shares of Cryo-Cell International Inc. (NYSEAMERICAN:CCEL – Free Report) by 40.4% in the second quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 14,064 shares of the company’s stock after buying an additional 4,046 shares during the quarter. Susquehanna International Group LLP owned approximately 0.17% of Cryo-Cell International worth $45,000 at the end of the most recent reporting period. 10.44% of the stock is owned by hedge funds and other institutional investors.
Cryo-Cell International Stock Performance
Shares of Cryo-Cell International stock traded down $0.10 during trading hours on Wednesday, hitting $4.28. The company’s stock had a trading volume of 11,502 shares, compared to its average volume of 16,766. The company has a market cap of $34.50 million, a PE ratio of -14.27 and a beta of 0.47. The business has a 50 day moving average price of $3.82 and a two-hundred day moving average price of $3.59. Cryo-Cell International has a 12-month low of $2.72 and a 12-month high of $5.01.
About Cryo-Cell International
Cryo-Cell International, Inc is a pioneering provider of umbilical cord blood and tissue preservation services. Headquartered in Oldsmar, Florida, the company was founded in 1989 as the first private cord blood bank in the United States. Cryo-Cell operates FDA-registered and AABB-accredited laboratory facilities, maintaining stringent quality control measures and cryogenic storage systems to safeguard stem cell viability over long-term storage periods.
The company’s primary business activity centers on the collection, processing and secure storage of newborn stem cell sources harvested at birth.
Featured Articles
- Five stocks we like better than Cryo-Cell International
- Holiday Shopping Is Almost Here—And Target May Be Ready to Win Big
- AI Panic Hit Tech Stocks—But NVIDIA’s Growth Engine Is Intact
- 5 Buy-and-Hold Stocks Built to Weather a Volatile Market
- Movado’s Turnaround Gains Momentum
Receive News & Ratings for Cryo-Cell International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cryo-Cell International and related companies with MarketBeat.com's FREE daily email newsletter.
